COMMUNIQUÉS West-GlobeNewswire

-
The Canadian Dermatology Association urges Canadians to protect themselves from skin cancer this summer
01/05/2024 -
L’Association canadienne de dermatologie incite les Canadiens à se prémunir contre les cancers de la peau cet été
01/05/2024 -
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
01/05/2024 -
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
01/05/2024 -
Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia
01/05/2024 -
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
01/05/2024 -
Pliant Therapeutics to Participate in Upcoming Investor Events
01/05/2024 -
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
01/05/2024 -
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
01/05/2024 -
Touro University Nevada College of Osteopathic Medicine Teaches Living Anatomy and Physiology with Vave Health Pocket Ultrasound
01/05/2024 -
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
01/05/2024 -
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
01/05/2024 -
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
01/05/2024 -
AltruBio to Participate in Upcoming May 2024 Medical Conferences
01/05/2024 -
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
01/05/2024 -
BetterLife Advances BETR-001 IND-enabling Studies
01/05/2024 -
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
01/05/2024 -
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01/05/2024 -
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
01/05/2024
Pages